Busulfan test dose

Phase 2Cell therapy

NNational Cancer Institute (NCI)

Busulfan test dose is one of 50 small molecule programs targeting Immunodeficiency. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImmunodeficiencyRecruiting

GATA2Recruiting

ImmunodeficiencyPhase 2

Recruiting

GATA2Phase 2

Recruiting

Competition

Competitive Landscape

296 competitors in Immunodeficiency

#DrugCompanyPhaseTrials

Farxiga

AstraZeneca

Phase 3

1 2

Emtriva

Gilead

Phase 3

1 3

Repatha

Amgen

Phase 3

1 4

Edurant Ped

WWim Janssens

Phase 3

8 5

Vemlidy

Gilead

Phase 3

—6

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 7

Livalo

MMedicure

Phase 3

1 8

Immunoglobulin

Sanofi

Phase 3

2 9

PPSV23

Merck & Co.

Phase 3

1 10

Darunavir/ritonavir

GSK

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Hematopoietic Stem Cell Transplant

NCT04339777

Q4 2028

Phase 2Recruiting

GATA2

NCT01861106

Q3 2031

Phase 2Recruiting

Immunodeficiency

NCT05027945

Clinical

Trials by Indication[1]

Hematopoietic Stem Cell Transplant1 trial

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04339777·66 enrolled

Immunodeficiency1 trial

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05027945·54 enrolled

GATA21 trial

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Mutations in GATA2 or the MonoMAC Syndrome

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT01861106·144 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Busulfan test dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Busulfan test dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Busulfan test dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

Busulfan test dose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2028

Q3 2031

Trials by Indication[1]

Hematopoietic Stem Cell Transplant1 trial

Immunodeficiency1 trial

GATA21 trial

References

Drug Info

Quick Facts

Related News